Sign up to access historical data
Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.7M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$183M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Mahadevia Ankit | Aug 27, 2024 | Sell | 5,912 | $1.35 | $8,000 |
| Keutzer Timothy | Aug 27, 2024 | Sell | 2,213 | $1.35 | $3,000 |
| Shukla Sath | Aug 27, 2024 | Sell | 2,757 | $1.35 | $3,700 |
| Shukla Sath | Aug 5, 2024 | Sell | 17,641 | $1.31 | $23,000 |
| Shukla Sath | Aug 2, 2024 | Sell | 14,800 | $1.32 | $20,000 |
| Shukla Sath | Feb 5, 2024 | Sell | 45,093 | $1.45 | $65,000 |
| Keutzer Timothy | Feb 2, 2024 | Sell | 30,971 | $1.36 | $42,000 |
| Mahadevia Ankit | Feb 2, 2024 | Sell | 63,795 | $1.37 | $87,000 |
| JOSEPH TAMARA L | Feb 2, 2024 | Sell | 30,906 | $1.37 | $42,000 |
| HAMED KAMAL | Feb 2, 2024 | Sell | 28,075 | $1.37 | $38,000 |
| Shukla Sath | Feb 2, 2024 | Sell | 30,901 | $1.37 | $42,000 |
| HAMED KAMAL | Sep 13, 2023 | Sell | 39,496 | $1.27 | $50,000 |
| Shukla Sath | Aug 29, 2023 | Sell | 4,163 | $1.3 | $5,400 |
| Keutzer Timothy | Aug 28, 2023 | Sell | 1,854 | $1.26 | $2,300 |
| JOSEPH TAMARA L | Aug 28, 2023 | Sell | 1,854 | $1.26 | $2,300 |
| Mahadevia Ankit | Aug 28, 2023 | Sell | 9,040 | $1.26 | $11,000 |
| Shukla Sath | Aug 28, 2023 | Sell | 1,854 | $1.26 | $2,300 |
| Mahadevia Ankit | Feb 3, 2023 | Sell | 12,286 | $1.81 | $22,000 |
| Keutzer Timothy | Feb 2, 2023 | Sell | 3,394 | $1.86 | $6,300 |
| JOSEPH TAMARA L | Feb 2, 2023 | Sell | 3,394 | $1.86 | $6,300 |
| Shukla Sath | Feb 2, 2023 | Sell | 9,504 | $1.8279 | $17,000 |
What's the latest insider transaction for Spero Therapeutics?
The most recent insider transaction for Spero Therapeutics was conducted by Mahadevia Ankit, who sold 5,912 shares on August 27, 2024 at a price of $1.35 per share.
Which insider has sold the most SPRO stock over the last two years?
Shukla Sath has sold the most SPRO stock in the last 2 years, with a total value of $180,000.
What is the total value of insider transactions for Spero Therapeutics (SPRO) in the last 2 years?
The total value of insider transactions for Spero Therapeutics in the last 2 years is negative, amounting to -$500,000. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Spero Therapeutics' market confidence?
Over the last 2 years, insider transactions for Spero Therapeutics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
